Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial

Andrea Z. Lacroix, Ellen W. Freeman, Joseph Larson, Janet S. Carpenter, Hadine Joffe, Susan D. Reed, Katherine M. Newton, Rebecca A. Seguin, Barbara Sternfeld, Lee Cohen, Kristine E. Ensrud

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Objective: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. Study design: A double-blind, placebo-controlled randomized trial of escitalopram 10-20 mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. Main outcome measures: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). Results: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p = 0.045). Conclusions: Treatment with escitalopram 10-20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalMaturitas
Volume73
Issue number4
DOIs
StatePublished - Dec 1 2012

Keywords

  • Antidepressants
  • Escitalopram
  • Menopausal quality of life
  • Randomized controlled trial
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Lacroix, A. Z., Freeman, E. W., Larson, J., Carpenter, J. S., Joffe, H., Reed, S. D., Newton, K. M., Seguin, R. A., Sternfeld, B., Cohen, L., & Ensrud, K. E. (2012). Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. Maturitas, 73(4), 361-368. https://doi.org/10.1016/j.maturitas.2012.09.006